Alterations of cell cycle regulators are less frequent in advanced non-small cell lung cancer than in resectable tumours

Lung Cancer

Volumn 33, Issue 2-3, 2001, Pages 229-239

  Gugger, M ^a   Kappeler, A ^a   Vonlanthen, S ^a   Altermatt, H J ^b   Ris, H B ^a   Lardinois, D ^a   Borner, M M ^a   Heighway, J ^c   Betticher, D C ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Pathology Langgasse   (Switzerland)

^c Roy Castle International Centre for Lung Cancer Research   (United Kingdom)

Author keywords

Cell cycle; Cyclin D1; Lung cancer; NSCLC; p14ARF; p16INK4a; Prognosis; Retinoblastoma protein; Stage

Indexed keywords

CYCLIN D1; PROTEIN P16; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ADULT; AGED; ARTICLE; CELL CYCLE; CELL CYCLE PARAMETERS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE; CELL CYCLE PROTEINS; CELL NUCLEUS; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROTEINS; RETINOBLASTOMA PROTEIN; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P14ARF; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034894586     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(01)00196-9     Document Type: Article

References (33)

1. Revisions in the International System for Staging Lung Cancer
2. Chemotherapy for advanced non small cell lung cancer
3. Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients
4. Tying it all together: epigenetics, genetics, cell cycle, and cancer
5. Cancer cell cycles
6. Tumor surveillance via the ARF-p53 pathway
7. G1 control gene status is frequently altered in resectable non-small cell lung cancer
8. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small cell lung cancer
9. Expression of p16INK4a/p16alpha and p14ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression
10. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small-cell lung cancer
11. Regression models and life-tables (with discussion)
12. Cell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer
13. Disruption of the RB pathway and cell-proliferative activity in non-small cell lung cancers
14. Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage
15. Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer
16. Mutational analysis of the CDKN2 gene in metastases from patients with cutaneous malignant melanoma
17. Involvement of the pRb/p16/CDK4/cyclin D1 pathway in the tumorigenesis of sporadic malignant melanomas
18. Inactivation of the CDKN2 gene by homozygous deletion and de novo methylation is associated with advanced stage esophageal squamous cell carcinoma
19. p53 protein accumulates frequently in early bronchial neoplasia
20. p53 expression in normal and dysplastic bronchial epithelium and in lung carcinomas
21. Detection and sequencing of p53 gene mutations in bronchial biopsy samples in patients with lung cancer
22. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines
23. Inversely correlated expression of p16 and Rb protein in non-small cell lung cancers: an immunohistochemical study
24. Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers
25. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2
26. Cyclin D1 expression in non-small cell lung cancers: its association with altered p53 expression, cell proliferation and clinical outcome
27. Prognostic significance of cyclin D1 and retinoblastoma expression in combination with p53 abnormalities in primary, resected non-small cell lung cancers
28. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification
29. Cyclin D1 and prognosis in human breast cancer
30. Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer
31. Sensitivity to cis-diamminedichloroplatinum in human cancer cells is related to expression of cyclin D1 but not c-raf1 protein
32. Inhibtion of basal and nitrogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum
33. Screening for lung cancer